These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 21295334)

  • 1. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Martinez A; Pomel C; Mery E; Querleu D; Gladieff L; Ferron G
    Gynecol Oncol; 2011 May; 121(2):258-63. PubMed ID: 21295334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic peripancreatic lymph nodes resection during primary debulking surgery for primary peritoneal serous carcinoma.
    Nishikimi K; Tate S; Matsuoka A; Sakai N; Otsuka M; Shozu M
    Gynecol Oncol; 2020 May; 157(2):555-557. PubMed ID: 32192733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
    Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
    Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended cytoreduction of tumor at the porta hepatis by an interdisciplinary team approach in patients with epithelial ovarian cancer.
    Song YJ; Lim MC; Kang S; Seo SS; Kim SH; Han SS; Park SY
    Gynecol Oncol; 2011 May; 121(2):253-7. PubMed ID: 21277009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Cowan RA; Tseng J; Murthy V; Srivastava R; Long Roche KC; Zivanovic O; Gardner GJ; Chi DS; Park BJ; Sonoda Y
    Gynecol Oncol; 2017 Nov; 147(2):262-266. PubMed ID: 28888540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Porta hepatis peritonectomy and hepato-celiac lymphadenectomy in patients with stage IIIC-IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes.
    Tozzi R; Traill Z; Garruto Campanile R; Ferrari F; Soleymani Majd H; Nieuwstad J; Hardern K; Gubbala K
    Gynecol Oncol; 2016 Oct; 143(1):35-39. PubMed ID: 27519966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
    Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
    Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
    Chi DS; Zivanovic O; Levinson KL; Kolev V; Huh J; Dottino J; Gardner GJ; Leitao MM; Levine DA; Sonoda Y; Abu-Rustum NR; Brown CL; Barakat RR
    Gynecol Oncol; 2010 Oct; 119(1):38-42. PubMed ID: 20609464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
    Chi DS; Franklin CC; Levine DA; Akselrod F; Sabbatini P; Jarnagin WR; DeMatteo R; Poynor EA; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2004 Sep; 94(3):650-4. PubMed ID: 15350354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
    Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
    Powless CA; Aletti GD; Bakkum-Gamez JN; Cliby WA
    Gynecol Oncol; 2011 Sep; 122(3):536-40. PubMed ID: 21636114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of residual tumor locations in advanced ovarian cancer patients after incomplete primary cytoreduction.
    Grabowskil JP; Mardas M; Markowska A; Markowska J
    Eur J Gynaecol Oncol; 2015; 36(3):274-7. PubMed ID: 26189252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
    Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
    Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasis to para-aortic lymph nodes cephalad to the renal veins in patients with ovarian cancer.
    Komiyama S; Nagashima M; Taniguchi T; Rikitake T; Morita M
    World J Surg Oncol; 2020 Apr; 18(1):64. PubMed ID: 32238145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.
    Nasser S; Lazaridis A; Evangelou M; Jones B; Nixon K; Kyrgiou M; Gabra H; Rockall A; Fotopoulou C
    Gynecol Oncol; 2016 Nov; 143(2):264-269. PubMed ID: 27586894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.